Ripple Science is leading the digital transformation in clinical trials, with a direct-to-patient software platform that was developed by researchers for researchers. Ripple enabled teams benefit from more secure workflows & data sharing concerning all aspects of patient engagement from first contact to last patient visit, whether virtual or in-person. For more information, go to www.ripplescience.com

Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more information, go to  www.signanthealth.com

SDC delivers top-tier technology enabled, clinical trial services to pharmaceutical, biologic, and medical device/diagnostic companies, providing the experienced teams the ability to meet your needs. With biometric services (biostatistics, data management, consulting) and technology solutions (EDC, IRT, ePRO, data analytics/warehousing) expertise, our services are scalable to provide full service clinical trial solutions. To learn more, please visit www.sdcclinical.com

The Patient Recruiting Agency™ (TPRA) is a full-service global recruiting/retention company working for Sponsors, CROs, & Investigators. For 25 years, TPRA has recruited over 10,000 patients of all genders, ages, and races in multiple languages for over 150 therapeutic indications. IN-HOUSE services include branding, content development, creative design, media placement, website development, online pre-screening, & RADIUS365™ tracking and reporting systems. Experienced. Flexible. Scalable. For more information, go to www.patientrecruiting.com.

Vivalink offers a Biometrics Data Platform for remote patient monitoring in clinical trials. It combines medical wearable sensors and advanced cloud data services to continuously capture patient vitals and biometrics in virtually any remote setting. Applications include ambulatory cardiac monitoring, neutropenic fever monitoring, and pulmonary hypertension assessment. To learn more, please visit www.vivalink.com

Yunu provides medical research technology and services to life sciences companies and clinical research environments that perform precision imaging assessments. Yunu’s aim is to ensure breakthrough therapies are accessible to everyone by unifying medical imaging insights and connecting clinical communities. With thousands of clinical trials relying on the platform each day, Yunu is delivering a new standard of oncology trial management. For more information, go to www.yunu.io

Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm.

TD2 provides innovative services for improved and accelerated development of medicines for cancer. Our team has deep experience and understanding in drug development. Preclinical development, combined with regulatory affairs expertise, guides customized clinical trial design and execution. Our capabilities encourage the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. For more information, go to www.td2inc.com

Elephas is developing an ex-vivo technology suite to assess how live tumor fragments (LTFs)TM respond to immunotherapies. We seek to remove the trial-and-error approach to cancer care by harnessing the latest advances in cancer biology, advanced imaging, and artificial intelligence to accelerate drug development and empower clinical decision-making. Our unique approach maintains the native 3-dimensional cellular architecture and micro-environment of the tumor, enabling rapid real-time characterization of live tumor sample response to immunotherapies. To learn more, visit us at www.elephas.com. 

radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organisation, optimising the development of new oncology treatments. radiomics.bio supports biotech and pharma companies in all stages of clinical development offering services including disease characterization, dose impact quantification, response evaluation, image biomarker identification and outcome predictions. With radiomics.bio you can quantify response for objective decision making, obtain early insights from clinical trials, explore and validate drug mechanisms of action, and increase your understanding of disease on a patient, organ, or lesion level for insight-based decision making. For more information, go to www.radiomics.bio

Scimega is a niche Canadian oncology CRO acting in Canada within the context of global cutting-edge oncology trials sponsored by mid-size and smaller biotechs. Skilled in collaborative vendor teaming, Scimega guarantees sponsors the quickest site start-up and highest patient recruitment rate, without sacrificing premium quality data. With an optimal operations design robust enough to address an ever-changing clinical trial landscape, Scimega’s team of Lean Coached oncology experts go above-and-beyond to provide: Local, full-time, permanent hires for exceptional staff quality; An extensive network of Canadian Investigator Sites that frequently emerge among top enrollers, and are activated 50% faster than average for global studies; Optimal site engagement to maximize quality, timely data entry and query resolution; Robust and Lean Scimega methodology and processes are supported by current technology to keep every trial this CRO monitors on the Lean trajectory.

To learn more about the Canadian opportunity or explore an expansion with Scimega, please visit: https://scimega.com/

PPD, part of Thermo Fisher Scientific, provides clinical development and analytical services that enhance customer innovation and productivity. Utilizing patient-centered strategies and data analytics, we cover multiple therapeutic areas and include early development, all phases of clinical development, peri- and post-approval, patient recruitment, investigator sites and comprehensive laboratory services. To learn more, visit https://www.ppd.com/